Anadys Pharmaceuticals to Present at Third Annual Needham Biotechnology Conference.

Business Editors/Health/Medical Writers

Third Annual Needham Biotechnology Conference

BIOWIRE2K

SAN DIEGO--(BUSINESS WIRE)--June 14, 2004

Presentation to be Webcast Live from New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of on June 16

Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS) announced today that it will be presenting at the Third Annual Needham Biotechnology Conference on Wednesday, June 16 at 10:00 a.m. Eastern Time at the New York Palace

Palace Theatre, New York
New York Palace, Budapest, Hungary

Hotel. Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and Chief Executive Officer, will present an overview of the Company and its lead programs, isatoribine and ANA975 for hepatitis C Hepatitis C Definition

Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. and ANA380 for hepatitis B Hepatitis B Definition

Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic . A live webcast of the presentation can be accessed at www.anadyspharma.com and will be available until June 30.

About Anadys Pharmaceuticals Inc.

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule, anti-infective medicines for the treatment of hepatitis C virus

This page is for the virus. For the disease, see Hepatitis C.

The Hepatitis C virus (HCV) is a small (50 nm in size), enveloped, single-stranded, positive sense RNA virus in the family Flaviviridae. , hepatitis B virus and bacterial infections. Anadys is advancing its anti-infective portfolio through the development of its two clinical programs, the isatoribine family of compounds and ANA380. In addition, Anadys' anti-infective therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.

COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Geographic Code:	1USA
Date:	Jun 14, 2004
Words:	199
Previous Article:	ALARIS Medical Systems Introduces Wireless Connectivity for Its Smart IV Medication Safety System.
Next Article:	RAE Systems Selects NetBotz IP-Based Security Solution to Bridge Wireless and Wired Sensor Networks.
Topics:	Pharmaceutical industry

Related Articles
Anadys Pharmaceuticals To Present at the BIO 2003 Annual Convention.
Anadys Pharmaceuticals Announces Initial Public Offering.
Anadys Pharmaceuticals Announces Exercise of Underwriters' Over-Allotment Option.
Anadys Pharmaceuticals Announces Move to Facility Located in the Torrey Mesa Area, San Diego, California; State-of-the-Art, Former Syngenta Facility...
Abgenix to Present at Needham & Company's Third Annual Biotechnology Conference.
Sonus Pharmaceuticals to Present at 2004 Needham Biotechnology Conference.
Anadys Pharmaceuticals Enters New Drug Discovery Collaboration with Roche; Second Alliance Builds on Success of Initial Collaboration.
Anadys Pharmaceuticals Strengthens Board of Directors with Addition of Douglas Williams, Ph.D.
Anadys Pharmaceuticals To Present at BIO Emerging Company Investor Forum on October 15, 2004.
Anadys Pharmaceuticals To Announce Third Quarter Financial Results and Clinical Development Plans on November 9, 2004.